The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease...
Date First Received: August 29, 2005
Last Updated: April 16, 2008
Verified by: UCB, April 2008
Clinical Trial Phase: Phase 3 | Start Date: January 2004
Overall Status: Completed
Brief Summary
Official Title: “A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease”
Condition Keyword(s):
Intervention(s):
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.
Study Type: Interventional
Study Design: Randomized, Open Label, Dose Comparison, Crossover Assignment
Study Primary Completion Date: May 2004
Detailed Clinical Trial Description
See approved Package Insert for Adverse Event information.
Intervention(s) in this Clinical Trial
- Drug: PARCOPA
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Stable Parkinson's Disease
Exclusion Criteria:
- Not using carbidopa/levodopa tablets
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Clinical Trial Sponsor Information
Lead Sponsor: UCB
Overall Clinical Trial Officials and Contacts
Patricia Witt Study Director UCB
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00139867
Study ID Number: SP780
ClinicalTrials.gov Identifier: NCT00139867
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
